本文關鍵詞：養(yǎng)肝益水顆粒對原發(fā)性高血壓早期腎損害的有效性及對炎癥因子影響的臨床觀察　出處：《安徽中醫(yī)藥大學》2016年碩士論文　論文類型：學位論文

  更多相關文章： 養(yǎng)肝益水顆粒 高血壓早期腎損害 臨床觀察 炎癥因子

【摘要】：目的:觀察養(yǎng)肝益水顆粒對原發(fā)性高血壓早期腎損害患者的療效及對相關炎癥因子的影響,并探討其作用機制,為養(yǎng)肝益水顆粒防治高血壓早期腎損害提供臨床依據(jù)。方法:病例選擇西醫(yī)確診為原發(fā)性高血壓早期腎損害,中醫(yī)辨證屬肝腎陰虛或兼夾血瘀證的患者50例,采用隨機、對照的方法,隨機分為治療組和對照組,每組均為25例。兩組均給予生活方式干預、西醫(yī)常規(guī)降壓等治療,治療組在對照組的基礎上加用養(yǎng)肝益水顆粒。兩組療程均為6周。療程結束后觀察兩組患者的中醫(yī)證候積分、尿白蛋白/肌酐、尿α1微球蛋白(al-MG)、尿微量白蛋白(m Al B)、尿轉(zhuǎn)鐵蛋白(TRF)、尿免疫球蛋白G(Ig GU)及尿β2微球蛋白(β2-MG)、超敏C反應蛋白(hs-CRP)、白介素-6(IL-6)、細胞間黏附分子-1(ICAM-1)及胱抑素C(Cys-C)等變化情況。結果:1.治療前兩組基線數(shù)據(jù)(年齡、性別、尿白蛋白/肌酐、尿微量蛋白、hs-CRP、IL-6、ICAM-1、Cys-C等)無統(tǒng)計學差異(p0.05);2.治療后,中醫(yī)證候積分方面治療組較對照組下降明顯(p0.05);3.治療后,兩組尿五蛋白及UACR均有不同程度的下降(p0.05或p0.01),但對照組的Ig GU、TRF及UACR下降無統(tǒng)計學意義;治療組的尿五蛋白下降較對照組更為顯著(p0.05或p0.01);4.治療后,兩組hs-CRP、IL-6均有所下降(p0.05),但治療組優(yōu)于對照組(p0.05)。5.治療后兩組ICAM-1及Cys-C均有所下降,但只有治療組的Cys-C下降具有統(tǒng)計學意義(p0.05)。結論:養(yǎng)肝益水顆粒能有效改善高血壓早期腎損害患者的臨床伴隨癥狀且安全性高,可有效降低患者尿微量蛋白、抑制hs-CRP、IL-6及Cys-C等相關炎癥因子的釋放。初步證實養(yǎng)肝益水顆�？赡苁峭ㄟ^抑制炎癥因子釋放,減輕腎臟細胞炎癥反應,從而延緩腎損害進程、保護腎臟功能。
[Abstract]:Objective: To observe the curative effect of YangGanYiShui Granule on primary hypertension patients with early renal damage and effects on inflammatory factors, and explore its mechanism, to provide clinical basis for early renal damage of YangGanYiShui Granule on prevention and treatment of hypertension. Methods: patients diagnosed with western medicine on early renal damage in hypertensive patients, TCM. 50 cases of patients with liver and kidney deficiency and blood stasis syndrome or using a randomized control method, were randomly divided into treatment group and control group, each group had 25 cases. The two groups were given lifestyle intervention, blood pressure and other conventional western medicine treatment, the treatment group in the control group based on the use of YangGanYiShui granule. Two groups were treated for 6 weeks. To observe the TCM syndrome integral of two groups of patients after treatment, urinary albumin / creatinine, urine alpha 1 microglobulin (al-MG), urinary albumin (m Al B), urinary transferrin (TRF), urinary immunoglobulin G (Ig GU) and urinary beta 2 寰悆铔嬬櫧(尾2-MG),瓚呮晱C鍙嶅簲铔嬬櫧(hs-CRP),鐧戒粙绱，

本文編號：1364213